<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02955602</url>
  </required_header>
  <id_info>
    <org_study_id>CB8025-21629</org_study_id>
    <nct_id>NCT02955602</nct_id>
  </id_info>
  <brief_title>Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)</brief_title>
  <official_title>An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CymaBay Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CymaBay Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to
      evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis
      (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary:

      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of
      treatment

      Secondary:

      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of
      treatment

      To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of
      treatment

      To evaluate the pharmacokinetics (PK) of MBX-8025

      Exploratory:

      To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and
      renal function

      MBX-8025 doses of 1 mg and 15 mg may be evaluated if dose adjustment occurs
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AE) and Treatment Emergent Adverse Events (TEAEs), ECG, biochemistry, hematology and urinalysis (NCI CTCAE Version 4.0)</measure>
    <time_frame>over 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl Transferase (GGT)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5'nucleotidase</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Total Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Conjugated Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin - Unconjugated Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Specific Alkaline Phosphatase (AP)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides (TG)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol (TC)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of AP and Total Bilirubin</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
    <description>AP &lt; 1.67 × upper limit of normal (ULN)
Total Bilirubin within normal limit
&gt; 15% decrease in AP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Paris I</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Paris II</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Toronto I</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Toronto II</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - UK-PBC Risk Score</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5D-itch Scale</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus Visual Analog Score (VAS)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PBC-40 Quality of Life (QoL)</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of MBX-8025 and Metabolites</measure>
    <time_frame>(at 0, 0.5, 1, 2, 4, 6 and 24 hours for Cmax, Tmax, T1/2, AUC and trough level)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Published PBC Response Criteria - Barcelona</measure>
    <time_frame>over 8 weeks, 12 weeks, 26 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>MBX-8025 (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 2 mg capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 5 mg capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBX-8025 (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBX-8025 10 mg capsule once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 2 mg Capsule</intervention_name>
    <description>Initial 8-week treatment:
• MBX-8025 2 mg
Extension:
The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.</description>
    <arm_group_label>MBX-8025 (2 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
    <other_name>seladelpar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 5 mg Capsule</intervention_name>
    <description>Initial 8-week treatment:
• MBX-8025 5 mg
Extension:
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.</description>
    <arm_group_label>MBX-8025 (5 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
    <other_name>seladelpar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBX-8025 10 mg Capsule</intervention_name>
    <description>Initial 8-week treatment:
• MBX-8025 10 mg
Extension:
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.</description>
    <arm_group_label>MBX-8025 (10 mg)</arm_group_label>
    <other_name>MBX-8025</other_name>
    <other_name>seladelpar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must have given written informed consent (signed and dated) and any authorizations
             required by local law

          2. 18 to 75 years old (inclusive)

          3. Male or female with a diagnosis of PBC, by at least two of the following criteria:

               -  History of AP above ULN for at least six months

               -  Positive AMA titers (&gt;1/40 on immunofluorescence or M2 positive by enzyme linked
                  immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies

               -  Documented liver biopsy result consistent with PBC

          4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to
             UDCA

          5. AP ≥ 1.67 × ULN

          6. Females of reproductive potential must use at least one barrier contraceptive and a
             second effective birth control method during the study and for at least 90 days after
             the last dose. Male subjects who are sexually active with female partners of
             reproductive potential must use barrier contraception and their female partners must
             use a second effective birth control method during the study and for at least 90 days
             after the last dose

        Exclusion Criteria:

          1. A medical condition, other than PBC, that in the investigator's opinion would preclude
             full participation in the study or confound its results (e.g., cancer on active
             treatment)

          2. AST or ALT &gt; 3 × ULN

          3. Total bilirubin &gt; 2.0 mg/dL

          4. Total bilirubin &gt; ULN AND albumin &lt; LLN with the exception to subjects with Gilbert's
             Syndrome. Subjects with Gilbert's syndrome are excluded if Direct Bilirubin &gt; ULN.

          5. Auto-immune hepatitis

          6. Primary sclerosing cholangitis

          7. Known history of alpha-1-Antitrypsin deficiency

          8. Known history of chronic viral hepatitis

          9. Creatine kinase above ULN

         10. Serum creatinine above ULN

         11. For females, pregnancy or breast-feeding

         12. Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months
             preceding screening

         13. Current use of fibrates or simvastatin

         14. Current use of obeticholic acid

         15. Use of an experimental or unapproved treatment for PBC

         16. Use of experimental or unapproved immunosuppressant

         17. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study
             (CB8025-21528)

         18. Any other condition(s) that would compromise the safety of the subject or compromise
             the quality of the clinical study, as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pol F Boudes, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CymaBay Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pol F Boudes, MD</last_name>
    <phone>510-293-8815</phone>
    <email>PBoudes@cymabay.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra (Sasha) Steinberg, MD, PhD</last_name>
    <phone>510-293-8817</phone>
    <email>ASteinberg@cymabay.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Kohli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein, MD</last_name>
      <phone>619-990-1698</phone>
      <email>THassanein@livercenters.com</email>
    </contact>
    <contact_backup>
      <last_name>Julio Gutierrez, MD</last_name>
      <phone>646-345-2492</phone>
      <email>jgutierrez@livercenters.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Standford University Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aparna Goel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Bowlus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aparna Goel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Neff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami - Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Levy, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Schiff</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates, LLC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Gitlin, MD</last_name>
      <phone>404-881-1094</phone>
    </contact>
    <contact_backup>
      <last_name>Cathy Williams, PA-C</last_name>
      <phone>404-881-1094</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael R Galambos, MD</last_name>
      <phone>404-355-3200</phone>
    </contact>
    <contact_backup>
      <last_name>Mark A Sims, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Flamm, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Thuluvath, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stuart C Gordon, MD</last_name>
      <phone>313-916-9465</phone>
      <email>sgordon3@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Pamela Drury, NP</last_name>
      <phone>313-283-0708</phone>
      <email>pdrury1@hfhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Borg, MD</last_name>
      <phone>601-984-4542</phone>
      <email>bborg@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>John Sheehan, MD</last_name>
      <phone>318-547-1577</phone>
      <email>Johnsheehanmd01@comcast.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint Louis University, Gastroenterology &amp; Hepatology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Bacon, MD</last_name>
      <phone>314-577-8764</phone>
      <email>baconcr@slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Center for Liver Disease and Transplantation</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernstein, MD</last_name>
      <phone>516-562-4664</phone>
    </contact>
    <contact_backup>
      <last_name>Tai-Ping Lee, MD</last_name>
      <phone>516-562-4664</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Stancia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Odin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Bach</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Northest Clinical Research Center, LLC.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Peyton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Investigation Drug Service</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlyn Mayo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Vierling, MD</last_name>
      <phone>713-798-4951</phone>
    </contact>
    <contact_backup>
      <last_name>Rise J Stribling, MD</last_name>
      <phone>(713) 798-4951</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of SA</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A Harrison, MD</last_name>
      <phone>210-614-1234</phone>
      <email>DrHarrison@gastroconsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Hays L Arnold, MD</last_name>
      <phone>210-614-1234</phone>
      <email>DrArnold@gastroconsa.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary's Immaculate Hospital</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Shiffman, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gunn</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Landis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary Liver Unit</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Swain, M.D.</last_name>
      <phone>403-592-5011</phone>
      <email>swain@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Meredith Borman, M.D.</last_name>
      <phone>403-210-3800</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Toronto Centre for Liver Disease</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemant Shah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic of Internal Medicine</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Dorffel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Kremer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Buggisch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center of Internal Medicine - Medical School of Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Manns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Centre of the Johannes Guttenberg-University</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Worns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Till Wissniowski, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitatsklinik Tubingen</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Berg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gideon Hirschfield, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Mells, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hull and East Yorkshire Hospitals NHS Trust</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynsey Corless, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Thorburn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sheridan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Aspinall, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <keyword>Primary Biliary Cholangitis (PBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

